Navigation Links
Gene Therapy May Treat Erectile Dysfunction
Date:5/20/2008

Studies in both men and monkeys show effectiveness of treatment

TUESDAY, May 20 (HealthDay News) -- Gene therapy may be a way to treat erectile dysfunction in men who do not respond to pills such as Viagra, researchers report.

Maxi-K gene therapy is a gene transfer that improves erectile dysfunction. Two studies using the gene were presented Tuesday at the American Urological Association's annual meeting, in Orlando, Fla.

"Gene transfer technology has the potential for long-term improvement for erectile function," lead researcher Dr. Arnold Melman, a professor of medicine at Albert Einstein College of Medicine in New York City, said during a morning teleconference Tuesday.

"The market for erectile dysfunction is quite large," Melman said. "And medications such as Viagra don't work very well in 40 percent of men."

Melman noted that a recent survey showed that 50 percent of urologists would consider switching their patients from their current medications to gene transfer treatment. "So, we think this will be well-accepted by physicians and patients," he said.

Results of a phase I trial testing gene transfer in 11 men with erectile dysfunction who had failed other therapy showed that gene transfer was safe and also had restorative effects. Four different doses were tried during the trial. Men receiving the highest dose showed improvement for up to six months, Melman said.

"These men had normal sexual function for six months and then went back to the way they were," Melman said. He added that two doses a year would be enough for most men to maintain their normal sexual function.

During two years of follow-up, none of the men reported any abnormalities after the gene transfer. The procedure was safe, and no adverse effects were seen, Melman said.

Based on these findings, Melman's group is moving on to new trials and hopes to have a product on the market within two years.

In another trial, four monkeys were fed a high-fat diet, which reduced their sex drive. After the monkeys received a Maxi-K gene transfer, they became friskier.

In addition, the number of partial and full erections increased about fivefold, the researchers found. Also, the frequency of ejaculations increased among the monkeys that received the gene transfer. Moreover, the gene transfer affected how the monkeys behaved with female monkeys.

"The most fascinating thing is there was the increased socialization," lead researcher George J. Christ, a professor of urology and head of the Program in Cell Tissue and Organ Physiology at the Wake Forest Institute for Regenerative Medicine, said during Tuesday's teleconference. "After receiving a gene transfer and regaining sexual function, they felt better about themselves."

More information

For more on erectile dysfunction, visit the National Institute of Diabetes and Digestive and Kidney Diseases.



SOURCES: May 20, 2008, teleconference with Arnold Melman, M.D., professor, medicine, Albert Einstein College of Medicine, New York City; George J. Christ, Ph.D., professor, urology, and head, Program in Cell, Tissue and Organ Physiology, Wake Forest Institute for Regenerative Medicine, Winston-Salem, N.C., May 20, 2008, presentations, American Urological Association annual meeting, Orlando, Fla.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Invasive methods unnecessary for prostate cancer radiation therapy treatment planning
2. A potential route for human tumor gene therapy
3. New patient satisfaction study with budesonide/formoterol combination therapy
4. Hormone Therapy Safe, Effective for Women Entering Menopause
5. Self Help Therapy for Veterans with Traumatic Brain Injury (TBI)
6. Personalized therapy for asthma and COPD could soon be here
7. Not All Colon Cancer Patients Need Chemotherapy: Study
8. New Therapy Kills Human Leukemia Cells in Mice
9. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
10. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
11. Adding epratuzumab to standard therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Therapy May Treat Erectile Dysfunction
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: